Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnerships
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnerships
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine > Articles > Policy > First voluntary licensing of cancer drug sets ‘vital precedent’ for the industry
  • Articles
  • Policy

First voluntary licensing of cancer drug sets ‘vital precedent’ for the industry

  • 16 November 2022
  • Esther Nakkazi

An agreement between Novartis and the Medicines Patent Pool to facilitate production in LMIC countries of generic versions of on-patent nilotinib is boosting efforts to improve access to essential cancer medicines.

First voluntary licensing of cancer drug sets ‘vital precedent’ for the industry
Total
28
Shares
28
0
0
0
0

The first voluntary licence for a patented cancer medicine was signed last month on the fringes of the 2022 World Cancer Congress in Geneva.

The agreement between the pharmaceutical company Novartis and the Medicines Patent Pool – a UN backed public health organisation – will allow manufacturers to produce generic versions of nilotinib, a cancer medicine used to treat people with chronic myeloid leukaemia (CML) who are resistant to, or cannot tolerate, imatinib (Glivec).

It follows the example of similar voluntary licences that have been negotiated with the Medicines Patent Pool in other disease areas such as HIV/AIDS and hepatitis C, and is expected to result in widening access to the drug among patients in low-income, and even some lower-middle income, countries.

The nilotinib agreement was brokered within the context of the Access to Oncology Medicines (ATOM) project set up earlier this year by the Union for International Cancer Control.

“This is the first time that we’re seeing that this voluntary licence model can be adapted and applied to cancer,” Melissa Rendler-Garcia, ATOM Coalition Project Leader, told Cancerworld. “It allows for a reduction in price sometimes by over 50–90%, which is translated into being able to be accessible and affordable for patients, particularly in low income countries,” she said.

“When you look at the Medicines Patent Pool, and you look at what they’ve been able to do for access to HIV medicines and TB – that model has worked very well, to make sure that those medicines are easily accessible and very cheaply. We want to do the same for cancer and this is the first time that that’s going to happen,” she said. “We are  going to use that as an example to keep on really working with the private sector, the industry, big pharma to be able to negotiate with other voluntary licences for other medicines in the future.”

“That model has worked very well for access to HIV medicines and TB. We want to do the same for cancer”

Charles Gore, executive director of the Medicines Patent Pool, welcomed the opportunity to add a cancer drug to the list of treatments for which voluntary licences have been agreed. “Access to high-quality cancer medicines is a crucial component of the global health response to the cancer burden, therefore I am delighted to be signing our first licence agreement with Novartis for a much-needed cancer treatment in low- and middle-income countries. Although the remaining patent life is relatively short, this voluntary licence in the non-communicable disease space sets a vital precedent that I hope other companies will follow.”

The agreement has been welcomed by Pat Garcia Gonzalez, founder and CEO of the Max Foundation, an international advocacy group that for the past 25 years has been supporting CML patients across the globe and helping them access the treatment they need.

“There is a very critical problem for access to CML treatment and diagnostics in low-and middle-income countries, and all creative strategies are needed to improve the situation,” she says.

“Generic manufacturers will need to come forward to produce and deliver these drugs, and patients will need to be able to afford them”

“Innovation in creating availability to medicines is critical and this first voluntary licensing of a cancer drug is an important step for industry. We hope it will encourage more pharmaceutical companies to innovate and consider new ways to help all patients get the medicines they need,” she says.

She warns, however, that the agreement will only make a difference if it results in more and cheaper generics actually making it to the market. “For this approach to succeed in helping CML patients, we will need generic manufacturers to come forward to utilise the license to produce, contract and deliver nilotinib, and understand that many governments in the low-income world are not prepared to procure these drugs so patients will need to be able to afford them.”

‘Affordable’ in the case of nilotinib means affordable within the everyday family budget, as the drug – as with all CML tyrosine kinase inhibitors – will generally have to be taken for the patient’s entire lifetime.

John Collins Kamili is executive director and chief pharmacist at Cipla Quality Chemical Industries, one of the largest pharmaceutical manufacturers in sub-Saharan Africa, located in Kampala, Uganda, which manufactures generic drugs for a number of indications including HIV/AIDS, malaria and hepatitis. Currently it produces no cancer drugs – but that is set to change, with the opening of a planned new oncology facility, says Kamili.

He points out that oncology treatments are among the most dynamic in terms of research and new medicines, and that most cancer drugs are therefore currently under patent protection. Even in low-income countries like Uganda, which are able to use certain exemptions to the World Trade Organization TRIPS (Trade-Related Aspects of Intellectual Property Rights) agreement, access to technology to manufacture generic cancer drugs is very difficult, he says. “So voluntary licensing is the quickest way to close the technology gap.”

Cipla is already manufacturing antiretroviral drugs for HIV under a Medicines Patent Pool arrangement, with these generic drugs being restricted to markets in ‘least developed countries’ (as designated by the UN).

For Dennis Olodi, Ag. Executive Director of the Uganda Cancer Society, it is the prospect of enouraging production at local levels that he sees as offering the greatest impact on improving access to cancer medicines. “Cancer services are over centralised. If this licensing will cater for devolution of medicines to the lower facilities, then it will go a long way in bridging drug delivery gaps,” he says. “It will help support the existing procurement and medicine supply systems.”

“If this licensing will cater for devolution of medicines to the lower facilities, it will go a long way in bridging drug delivery gaps”

There may be limits, however, to how far the patent pooling model that has delivered well for HIV and other diseases can work for cancer. A survey published in the Lancet Oncology at the end of 2021 showed that the priority drugs listed by oncologists working in low and lower-middle income countries – the ones they felt would help them deliver the most for their patients – were primarily not the more recent drugs that are still protected by patents. What they want – and often lack – are the basic chemotherapy ‘workhorse’ drugs: anthracyclines, taxanes, platinum drugs, alkylating agents. Despite these having been off-patent for years, even decades, access remains hugely challenging.

“Among the top 20 medicines selected by oncologists in low-income and lower-middle-income countries, between 13% and 68% of respondents indicated that accessing each of these drugs placed patients at risk of catastrophic expenditure,“  reported the authors. “This was the case even for older generic cytotoxic drugs such as doxorubicin and cisplatin, with 27% of oncologists reporting a substantial risk of catastrophic financial expenditures for doxorubicin and 21% for cisplatin. Of the top 20 medicines listed for low-income lower-middle-income countries, dexamethasone was the only medication that was universally available for more than 50% of respondents.”

The Lancet study raises questions both about how far access programmes should focus on new generations of cancer drugs, and about assumptions that when a drug comes off patent, affordable generic versions become accessible in lower-income countries. Access to cancer medicine requires manufacturers like Cipla to start supplying affordable generic nilotinib, but also the many other cancer drugs that are at the top of oncologists’ priority lists.

Total
28
Shares
Share 28
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • Essential cancer medicines
  • generics
  • LMICs
  • Medicines Patent Pool
  • patents
Esther Nakkazi

Esther Nakkazi is a freelance Science and Technology Reporter. She writes for various media outlets around the globe and is also a media trainer and mentors journalists in science reporting and blogger at Uganda ScieGirl. She is the founder of the Health Journalists Network in Uganda. 

Previous Article
  • Supported contents

Digital Solutions in Cancer Care: from Prevention to Diagnosis

  • 11 November 2022
  • Adriana Albini
View Post
Next Article
  • News

Knowing ‘functional prognosis’ helps cancer patients plan unfinished business

  • 16 November 2022
  • Janet Fricker
View Post
You May Also Like
View Post
  • Articles
  • Delivery of Care

‘Fragile’ cancer patients hit by Turkish earthquake need urgent support

  • Marwa Koçak
  • 22 March 2023
View Post
  • Articles
  • Delivery of Care

Expert cancer surgery: could VR help speed up and standardise training?

  • Simon Crompton
  • 22 March 2023
View Post
  • Articles
  • Medicine

Immunotherapy: three studies point to potential strategies to improve response

  • Janet Fricker
  • 10 March 2023
View Post
  • Articles
  • Biology basic

A blood test for early detection of any cancer: What’s the ideal? Are we getting there?

  • Rachel Brazil
  • 10 March 2023
View Post
  • Articles
  • Delivery of Care

Food insecurity: Why screening for access to nutrition should be part of cancer treatment everywhere

  • Swagata Yadavar
  • 24 February 2023
View Post
  • Articles
  • Delivery of Care

Cancer care in Ukraine, one year on

  • Agnieszka Witkowicz-Matolicz
  • 22 February 2023
View Post
  • Articles
  • Policy

The cancer patients still struggling to access drugs in the wake of anti-corruption reforms

  • Giselle Vidal
  • 27 January 2023
View Post
  • Articles
  • Delivery of Care

Immunotherapy: outcomes of ultra low-dose trial offer hope for better global access

  • Swagata Yadavar
  • 26 January 2023

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Improving outcomes in elderly patients taking multiple medications
    • 24 March 2023
  • Localised prostate cancer: active monitoring offers valid option
    • 24 March 2023
  • Radiotherapy can be safely omitted in older women with low-risk breast cancer
    • 10 March 2023
  • Plant-based diets cut risk of prostate cancer progression and recurrence by over 50%
    • 9 March 2023
  • A blood test to recognize prostate cancer
    New prostate cancer blood test combining PSA with epigenetic test could reduce biopsies
    • 23 February 2023
Article
  • ‘Fragile’ cancer patients hit by Turkish earthquake need urgent support
    • 22 March 2023
  • Expert cancer surgery: could VR help speed up and standardise training?
    • 22 March 2023
  • Immunotherapy: three studies point to potential strategies to improve response
    • 10 March 2023
Latest printed issue
Social

Would you follow us ?

Contents
  • AI in Surgery
    • 8 March 2023
  • COVID and haematological malignancies
    • 28 February 2023
  • Telemedicine Rehabilitation in the Cancer Care Continuum
    • 24 February 2023
MENU
  • About the Magazine
    • Editorial Team
    • Leadership and Management
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnerships
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancerworld Magazine
  • About the Magazine
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by SPCC Sharing Progress in Cancer Care | Via Vincenzo Vela 6, 6500 Bellinzona - Switzerland | info@spcc.net

Archivio Cancerworld

Input your search keywords and press Enter.